Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1980 Jan 12;280(6207):69–72. doi: 10.1136/bmj.280.6207.69

Incidences of fatal postoperative pulmonary embolism after prophylaxis with dextran 70 and low-dose heparin: an international multicentre study.

U F Gruber, T Saldeen, T Brokop, B Eklöf, I Eriksson, I Goldie, L Gran, M Hohl, T Jonsson, S Kristersson, K G Ljungström, T Lund, H M Moe, E Svensjö, D Thomson, J Torhorst, A Trippestad, M Ulstein
PMCID: PMC1600226  PMID: 7353128

Abstract

A total of 4352 patients were admitted to a prospective' randomised multicentre trial comparing the prophylactic efficacy of dextran 70 and low-dose heparin against fatal pulmonary embolism after elective operations for general, orthopaedic, urological, and gynaecological conditions. Out of 3984 patients correctly admitted, 1993 were allocated to receive dextran 70 and 1991 to receive low-dose heparin. Withdrawal of prophylaxis because of bleeding or technical difficulties occurred more often in the heparin group, but allergic reactions were more common in the dextran group. Of the 75 patients who died within 30 days after operation, 38 had been given dextran and 37 low-dose heparin. Necropsy was performed in 33 and 32 of these cases respectively. In six patients in each group pulmonary embolism was the sole or a contributory cause of death. Of these, five patients in the dextran group and two in the heparin group had received a full course of prophylaxis. There was no statistically significant difference between the two treatment groups in the incidence of fatal pulmonary embolism after a full course of prophylaxis.

Full text

PDF
71

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bagge L., Saldeen T. The primary fibrinolysis inhibitor and trauma. Thromb Res. 1978 Dec;13(6):1131–1136. doi: 10.1016/0049-3848(78)90242-6. [DOI] [PubMed] [Google Scholar]
  2. Bergentz S. E. Dextran in the prophylaxis of pulmonary embolism. World J Surg. 1978 Jan;2(1):19–25. doi: 10.1007/BF01574452. [DOI] [PubMed] [Google Scholar]
  3. Carlin G., Saldeen T. Effect of dextran on fibrinolysis inhibition activity in serum. Thromb Res. 1978 Jun;12(6):1165–1175. doi: 10.1016/0049-3848(78)90071-3. [DOI] [PubMed] [Google Scholar]
  4. Gruber U. F. Dextran and the prevention of postoperative thromboembolic complications. Surg Clin North Am. 1975 Jun;55(3):679–696. doi: 10.1016/s0039-6109(16)40642-0. [DOI] [PubMed] [Google Scholar]
  5. Hedin H., Richter W., Ring J. Dextran-induced anaphylactoid reactions in man: role of dextran reactive antibodies. Int Arch Allergy Appl Immunol. 1976;52(1-4):145–159. doi: 10.1159/000231676. [DOI] [PubMed] [Google Scholar]
  6. Kakkar V. V. The current status of low-dose heparin in the prophylaxis of thrombophlebitis and pulmonary embolism. World J Surg. 1978 Jan;2(1):3–18. doi: 10.1007/BF01574449. [DOI] [PubMed] [Google Scholar]
  7. Kiil J., Kiil J., Axelsen F., Andersen D. Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin. Lancet. 1978 May 27;1(8074):1115–1116. doi: 10.1016/s0140-6736(78)90297-0. [DOI] [PubMed] [Google Scholar]
  8. Kline A., Hughes L. E., Campbell H., Williams A., Zlosnick J., Leach K. G. Dextran 70 in prophylaxis of thromboembolic disease after surgery: a clinically oriented randomized double-blind trial. Br Med J. 1975 Apr 19;2(5963):109–112. doi: 10.1136/bmj.2.5963.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet. 1975 Jul 12;2(7924):45–51. [PubMed] [Google Scholar]
  10. Ring J., Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977 Feb 26;1(8009):466–469. doi: 10.1016/s0140-6736(77)91953-5. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES